Purpose Intrauterine Growth Restriction (IUGR) is the inability of the fetus to achieve the biologically accessible growth potential. Irisin is a recently discovered adipomyokine with a crucial role in energy metabolism. Our current study aimed to investigate the relationship between the isolated IUGR in the third trimester and maternal serum irisin level. Materials and methods This prospective case-control study included total 137 pregnant women who were between the 24th and 39th gestational weeks and who applied to the University of Health Sciences, Ankara Zekai Tahir Burak Women's Health Training and Research Center, between 2016 October-2017 May. The Study Group consisted of 68 pregnant women who were diagnosed with Isolated IUGR with Estimated Fetal Weight (EFW) <10th percentile. The Control Group consisted of 69 low-risk uncomplicated pregnant women, matched with the Study Group in terms of gestational week, and with EFW between 10th and 90th percentiles. Demographic data, clinical findings, fetal Doppler parameters, and obstetric-neonatal outcomes were evaluated. Maternal serum irisin levels were measured by ELISA (Enzyme-Linked Immunosorbent Assay) Method and compared between the groups. Results Maternal serum irisin level was found to be significantly lower in IUGR Group as compared to the Control (3.83 ng/ml vs. 4.78 ng/ml, p < .001, respectively). There was a positive correlation between maternal serum irisin level and duration of pregnancy, the weight gain during pregnancy, birth weight, fetal abdominal circumference measurement and cerebroplacental ratio (r = 0.18, p = .03; r = 0.17, p = .04; r = 0.37, p < .001; r = 0.35, p < .001; r = 0.27, p = .001, respectively). Binary Logistic Regression Analysis showed that maternal serum irisin level is an independent estimator of IUGR [OR %95 CI: 8.33 (3.22 − 25.01)]. AUC (Area Under the Curve) analysis of maternal irisin for IUGR estimation was 0.75 (p < .001, 95% CI = 0.67 − 0.82). The optimal cutoff value was below 3.86 ng/ml for maternal irisin level with a sensitivity of 54.41% and a specificity of 88.41%, positive predictive value of 82.22% and negative predictive value of 66.30%. Conclusion Low level of maternal serum irisin in pregnancies with isolated IUGR was consistent with the role of irisin in metabolic pathways and with the increased risk of metabolic diseases in the future life of IUGR fetuses and their mothers.

Study the role of maternal irisin levels with preterm and term delivery

Abstract Background: The aim of our study was to find out whether exercise of the pelvic muscles during vaginal delivery increases maternal and cord blood irisin levels. Methods: This prospective study included 20 patients who vaginally delivered their babies and 20 patients that underwent elective cesarean section. In the vaginal delivery group, delivery occured either spontaneously or by induction. In the other group, the patients were electively operated before uterine contractions started. We compared serum irisin levels of the two groups and cord blood irisin levels of the babies of these mothers. Results: There was no statistically significant difference in maternal serum irisin levels between the two groups (p&gt;0.05). We also found no statistically significant difference in cord blood irisin levels (p&gt;0.05). The positive correlation between maternal and cord blood irisin levels was found to be statistically significant (p&lt;0.05). We also detected a significant positive correlation between maternal irisin levels and BMI in our study (p&lt;0.05). Conclusions: Irisin is a challenging molecule. Although we did not find a significant difference in the irisin levels of women according to the method of delivery, we feel that further investigations are warranted.

Effects of delivery on maternal & neonatal irisin levels in normal and preeclamptic pregnant women.